Abstract

Sun Pharmaceutical Industries, a multinational pharmaceutical company and one of the major players in the generic drug market in India, already had 16 successful acquisitions in its kitty when it acquired Ranbaxy in April 2014. The acquisition was expected to make the combined entity the 5th largest generic drug making company in the world and the largest in India. Ranbaxy had run into trouble with the FDA over regulatory issues in the past. The case deals with the future growth prospects, possible difficulties, and challenges that Sun Pharma could face post merger.

Learning Objectives

The case is structured to achieve the following Learning Objectives:

• The strategies companies in the pharmaceutical sector follow.
• The complexities involved in the merger and acquisition of two big players in the same industry.

Keywords

Sun Pharma Ranbaxy merger, Sun Pharma, Ranbaxy, Daiichi, ANDA, FDA, generic drug, regulatory issues, SEBI, CCI, acquisition, pharmaceutical industrys